Literature DB >> 16282533

HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.

Robert L Caldwell1, Radhika Gadipatti, Kirk B Lane, Virginia L Shepherd.   

Abstract

The bone morphogenetic protein receptor-2 (BMPR2) is a member of the transforming growth factor-beta receptor family and is expressed on the surface of several cell types including endothelial cells and macrophages. Recently, a cause for familial primary pulmonary hypertension (FPPH) has been identified as mutations in the gene encoding BMPR2. Three forms of pulmonary hypertension (PH) exist, including PPH, FPPH, and PH secondary to other etiologies (sporadic PH) such as drug abuse and human immunodeficiency virus (HIV) infection. It is interesting that these subtypes are histologically indistinguishable. The macrophage is a key target cell for HIV-1, significantly altering macrophage cell function upon infection. HIV-1 trans-activator of transcription (Tat), an immediate-early product of the HIV-1 lifecycle, plays an important role in mediating HIV-induced modulation of host cell function. Our laboratory has previously shown that Tat represses mannose receptor transcription in macrophages. In the current study, we examined activity from the BMPR2 promoter in the macrophage cell line U937 and potential regulation by Tat. Transfection of U937 cells with BMPR2 promoter-reporter constructs revealed dose-dependent repression of BMPR2 promoter activity in the presence of Tat. Experiments using truncations of the BMPR2 promoter localized Tat-mediated repression to the first 208 bases of the promoter. Decreased BMPR2 transcription resulted in altered downstream signaling. Similar to mothers against decapentaplegics (SMAD) phosphorylation and SMAD6 expression, in response to BMP2 treatment, were down-regulated after Tat treatment. Finally, HIV-1 infection and treatment with Tat protein of the U937 human monocytic cell line resulted in a decreased, endogenous BMPR2 transcript copy number.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282533     DOI: 10.1189/jlb.0405194

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

1.  Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective.

Authors:  Sharilyn Almodovar; Stefania Cicalini; Nicola Petrosillo; Sonia C Flores
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

2.  Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension.

Authors:  Pranjali Dalvi; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-09-05       Impact factor: 8.311

3.  Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension.

Authors:  Amie K Lund; Joann Lucero; Lindsay Herbert; Yushi Liu; Jay S Naik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-06-17       Impact factor: 5.464

4.  Pulmonary vascular lesions are common in SIV- and SHIV-env-infected macaques.

Authors:  M Patricia George; Alexandra Brower; Heather Kling; Tim Shipley; Jan Kristoff; Todd A Reinhart; Michael Murphey-Corb; Mark T Gladwin; Hunter C Champion; Alison Morris; Karen A Norris
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

Review 5.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

Review 6.  Human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Christopher F Barnett; Priscilla Y Hsue
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

7.  Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein.

Authors:  Thangavel Samikkannu; Zainulabedin M Saiyed; K V K Rao; Dakshayani Kadiyala Babu; Jose W Rodriguez; Marina N Papuashvili; Madhavan P N Nair
Journal:  AIDS Res Hum Retroviruses       Date:  2009-03       Impact factor: 2.205

8.  Antiviral activity of bone morphogenetic proteins and activins.

Authors:  Lucy A Eddowes; Kinda Al-Hourani; Narayan Ramamurthy; Jamie Frankish; Hannah T Baddock; Cynthia Sandor; John D Ryan; Dahlene N Fusco; João Arezes; Eleni Giannoulatou; Sara Boninsegna; Stephane Chevaliez; Benjamin M J Owens; Chia Chi Sun; Paolo Fabris; Maria Teresa Giordani; Diego Martines; Slobodan Vukicevic; John Crowe; Herbert Y Lin; Jan Rehwinkel; Peter J McHugh; Marco Binder; Jodie L Babitt; Raymond T Chung; Matthew W Lawless; Andrew E Armitage; Caleb Webber; Paul Klenerman; Hal Drakesmith
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

Review 9.  Human immunodeficiency virus and pulmonary arterial hypertension.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Aram Barbaryan; Suartcha Prueksaritanond
Journal:  ISRN Cardiol       Date:  2013-08-21

Review 10.  Maintaining lung health with longstanding HIV.

Authors:  Paul Collini; Alison Morris
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.